聚乙二醇化干扰素-α2a时代慢性髓性白血病女性患者的妊娠结局：卡塔尔的经验
Outcome of Pregnancy in the Era of PEGylated Interferon-α2a in Females with Chronic Myeloid Leukemia: An Experience from Qatar.
作者信息
Abu-Tineh Mohammad, Kassem Nancy, Abdulla Mohammad Abdul-Jaber, Ismail Omar Mohammad, Obeidat Khaldun, Ghasoub Rola, Yassin Mohamed A
机构信息
Department of Medical Education, Hamad Medical Corporation, Doha, Qatar.
National Center for Cancer Care and Research, Department of Pharmacy, Doha, Qatar.
出版信息
Case Rep Oncol. 2020 Mar 24;13(1):291-294. doi: 10.1159/000506590. eCollection 2020 Jan-Apr.
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative neoplasm characterized by increased proliferation of the granulocytic cell line without loss of its capacity to differentiate. It accounts for 20% of all adults affected by leukemia. Tyrosine kinase inhibitors revolutionized the treatment for CML and improved quality of life. Fertility is an important issue for both males and females. Here, we report our experience with a pregnant female with CML, and shed light on safety and efficacy of PEGylated interferon-αa in pregnant women with CML and its outcome.
慢性粒细胞白血病（CML），也称为慢性髓性白血病，是一种骨髓增殖性肿瘤，其特征是粒细胞系增殖增加且不失分化能力。它占所有白血病成年患者的20%。酪氨酸激酶抑制剂彻底改变了CML的治疗方法并改善了生活质量。生育能力对男性和女性来说都是一个重要问题。在此，我们报告我们对一名患有CML的孕妇的治疗经验，并阐明聚乙二醇化干扰素-α在患有CML的孕妇中的安全性、有效性及其治疗结果。
Zotero 插件